GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » BioCorRx Inc (OTCPK:BICX) » Definitions » Gross Profit

BioCorRx (BioCorRx) Gross Profit : $0.05 Mil (TTM As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is BioCorRx Gross Profit?

BioCorRx's gross profit for the three months ended in Dec. 2023 was $0.01 Mil. BioCorRx's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was $0.05 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. BioCorRx's gross profit for the three months ended in Dec. 2023 was $0.01 Mil. BioCorRx's Revenue for the three months ended in Dec. 2023 was $0.02 Mil. Therefore, BioCorRx's Gross Margin % for the quarter that ended in Dec. 2023 was 31.58%.

BioCorRx had a gross margin of 31.58% for the quarter that ended in Dec. 2023 => Competition eroding margins

During the past 13 years, the highest Gross Margin % of BioCorRx was 92.99%. The lowest was 21.95%. And the median was 70.59%.


BioCorRx Gross Profit Historical Data

The historical data trend for BioCorRx's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioCorRx Gross Profit Chart

BioCorRx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.16 0.03 0.04 0.20 0.05

BioCorRx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.03 0.01 0.01 0.01

Competitive Comparison of BioCorRx's Gross Profit

For the Medical Care Facilities subindustry, BioCorRx's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioCorRx's Gross Profit Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, BioCorRx's Gross Profit distribution charts can be found below:

* The bar in red indicates where BioCorRx's Gross Profit falls into.



BioCorRx Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

BioCorRx's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=0.089 - 0.036
=0.05

BioCorRx's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=0.019 - 0.013
=0.01

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.05 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

BioCorRx's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.01 / 0.019
=31.58 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


BioCorRx  (OTCPK:BICX) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

BioCorRx had a gross margin of 31.58% for the quarter that ended in Dec. 2023 => Competition eroding margins


BioCorRx Gross Profit Related Terms

Thank you for viewing the detailed overview of BioCorRx's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


BioCorRx (BioCorRx) Business Description

Traded in Other Exchanges
N/A
Address
2390 East Orangewood Avenue, Suite 500, Anaheim, CA, USA, 92806
BioCorRx Inc through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders. The BioCorRx Recovery Program is a non-addictive, medication-assisted treatment program for substance abuse that includes peer recovery support. The UnCraveRx Weight Loss Management Program is a medically assisted weight management program that is combined with a virtual platform application.
Executives
Louis C. Lucido director 2390 EAST ORANGEWOOD AVENUE, SUITE 500, ANAHEIM CA 92806
Joseph J Galligan director, 10 percent owner 333 SOUTH GRAND AVENUE, 18TH FLOOR, LOS ANGELES CA 90071
Harsha Murthy director 5209 38TH STREET,NW, WASHINGTON DC 20015
Luisa Ingargiola director 4826 BLUE JAY CIRCLE, PALM HARBOR FL 34683
Thomas Patrick Welch officer: Vice President of Operations 10453 SARAH ST., TOLUCA LAKE CA 91602
Kent Emry director, officer: Chief Executive Officer 2390 EAST ORANGEWOOD AVENUE, SUITE 500, ANAHEIM CA 92806
Brady James Granier director 13024 DELANO STREET, VALLEY GLEN CA 91401
Lourdes Felix director, officer: Chief Financial Officer 15 CALLE VERANO, RANCHO SANTA MARGARITA CA 92688
Jorge Jr Andrade director, officer: Chief Executive Officer PO BOX 5366, SANTA ANA CA 92704
Muller Neil Terrence Mr director, officer: President 13231 SANDHURST PLACE, SANTA ANA CA 92705